Laminitis is one of the cruellest conditions in the equine world. It can strike any horse, at any age — a sudden failure deep within the hoof, where the delicate lamina that bonds the hoof wall to the coffin bone breaks down. That bond is meant to hold like velcro. When it fails, the pain is severe, the damage can be permanent, and for too many horses the outcome is fatal.
For decades, the response has barely changed: manage the pain, rest the horse, and hope. Conventional care treats the symptoms while the underlying tissue continues to deteriorate. There has never been a widely available, approved treatment that targets the disease itself.
Byrock Technologies exists to change that.
Our lead candidate, PTP-102, is designed to act on the cause rather than the symptom. It works as a free-radical scavenger, calming the enzymatic cascade that drives the destruction of lamellar tissue — with the potential to be used both to prevent laminitis in at-risk horses and to treat it once it strikes. It is a fundamentally different approach to a problem the industry has managed, but never solved.
PTP-102 is built on solid foundations. Its active molecule has an extensive human safety record from large-scale clinical use, and our work is supported by peer-reviewed research published in Frontiers in Microbiology, alongside encouraging laboratory and field studies. PTP-102 has been granted FDA Minor Use / Minor Species (MUMS) status, placing it on a recognised regulatory pathway toward conditional approval.
PTP-102 is an investigational product and is not yet approved by any regulatory authority. It is in active development, advanced by a team that brings together veterinary, scientific, regulatory and commercial expertise — and a shared determination to bring a genuine treatment to the horses and owners who need it.
We are not interested in managing this disease. We intend to change how it is treated.
PTP-102
The only effective treatment for laminitis* in horses.
“PTP-102 exhibited notable success in treating laminitis by targeting the deactivation of MMPs, thereby stimulating the reconstruction of damaged lamellar and basement structures. Its impact on alleviating clinical symptoms and systemic inflammatory responses also significant.” ¬ Dr. Maimaiti Tuniyazi | Jilin University
PTP-102 is a novel synthetic nonglucocorticoid 21-aminosteroid that is designed to inhibit the range of metalloprotease enzymes and inflammatory cytokines which are the principal causative agents of equine laminitis.
PTP-102 can be used both therapeutically and prophylactically against laminitis. It has shown the ability to prevent and treat equine laminitis in just 72 hours. A condition that has long been considered untreatable.
PTP-102 is to be administered intravenously by a qualified vet.
PTP-102 is a unique treatment because it specifically targets the biochemical pathways involved in laminitis, offering a more focused approach compared to general anti-inflammatory or pain relief medications.
*Laminitis: definition
Laminitis is a disease that affects the feet of hooved animals (ungulates) and it is found mostly in horses and cattle. Clinical signs include foot tenderness progressing to inability to walk, increased digital pulses, and increased temperature in the hooves. Severe cases with outwardly visible clinical signs are known by the colloquial term founder, and progression of the disease may lead to perforation of the coffin bone through the sole of the hoof, requiring aggressive treatment or euthanasia.
https://dictionary.babylon-software.com/laminitis/